I was excited to learn that Fiasp, an extremely fast-acting insulin that I first heard about earlier this year, finally received FDA approval back in September. Fiasp had been available in the UK for a little while already, so it's big news that it's finally been approved here.
Reading up a little on Fiasp, what I've found is that it doesn't seem to have a shorter overall time than Humalog and Novolog, the other two major fast-acting insulins that are used today. Fiasp supposedly hits its peak between 1 and 3 hours, and stays in your system for 3 to 5 hours, which sounds pretty similar to its competitors.
What's different about Fiasp is that it starts working so much faster.
Humalog and Novolog don't start working for about 10 or 15 minutes, which leads a lot of people to pre-bolus before eating. (I don't have the patience for that so I never have, and after trying it a couple of times on the 670G I found that it actually doesn't work very well for me anyway.)
Fiasp, on the other hand, starts working within a couple of minutes. That kind of immediate effect is amazing!
With new technology like Medtronic's hybrid closed loop 670G, I wonder how this new, faster-acting insulin will impact these "artificial pancreases." I mean, they're not really artificial pancreases, they're only the closest approximation our technology can currently sustain, but the better the technology -- and the insulin -- gets, the closer we get to a true artificial pancreas.
With all these advancements lately in diabetes technology and treatment, I am excited to see how it will change and improve in the coming years!